Pharmacokinetics of Single Dose Oral EC5026 in Chronic Kidney Disease

Phase 1, open-label trial of EC5026 in pain (3 arms), sponsored by EicOsis Human Health. Primary endpoints: Area under the plasma concentration-time curve from time 0 to the last measurable concentration at 14 days, Area under the plasma concentration-time curve from time 0 extrapolated to infinity at 14 days and 9 more. Started Jul 2026; status: recruiting.